July 9, 2025 – Talk Bio

AstraZeneca’s Alexion Signs $825M AAV Capsid Deal with JCR Pharma

4 days ago talkbio0Tagged AAVS1 gene, Alexion, AstraZeneca, Capsid, gene therapy, genomic medicines, Infrequent, JCR, JUST-AAV, Licensing Deal

AstraZeneca; Alexion; JCR Pharmaceuticals; JUST-AAV; gene therapy; AAV capsid; rare disease; licensing deal; genomic medicines

Revolution Medicines and Iambic Announce $25M AI-Powered Drug Discovery Collaboration

4 days ago talkbio0Tagged Aortic Valve Insufficiency, Artificial Intelligence, Collaboration, Drug Discovery, Drug Industry, Iambic Therapeutics, milestone payments, Neoplasms, NeuralPLexer, propane, RAS-addicted cancers, Revolution Medicines

Revolution Medicines; Iambic Therapeutics; AI drug discovery; NeuralPLexer; PropANE; oncology; RAS-addicted cancers; collaboration; pharmaceutical industry; milestone payments

Novartis Gains World-First Approval of Malaria Treatment for Babies

5 days ago talkbio0Tagged Africa, Approved, artemether-lumefantrine, Coartem, Infant, Infant, Newborn, Malaria, Novartis, Swissmedic, venture

Novartis; malaria; Coartem Baby; Swissmedic; newborns; infants; Africa; approval; artemether-lumefantrine; Medicines for Malaria Venture; not-for-profit

Taiho’s Investigational DMD Therapy Misses Primary Endpoint in Phase 3 Trial

5 days ago talkbio0Tagged Clinical trial failure, Muscular Dystrophy, Duchenne, Otsuka Holdings, pizuglanstat, REACH-DMD study, Taiho, TAS-205

Taiho; Duchenne muscular dystrophy; DMD; pizuglanstat; TAS-205; Phase 3 trial; clinical trial failure; REACH-DMD study; Otsuka Holdings